A Phase 3, Randomized, Observer-Blinded, Study to Compare the Safety and Immunogenicity of 3 Lots of SARS-CoV-2 rS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of Age

Publication date: Jun 27, 2024

The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 60+

Type	Source	Name
disease	MESH	Influenza
disease	VO	combination vaccine
disease	VO	age
disease	IDO	immune response
disease	MESH	COVID-19
disease	MESH	treatment failure
disease	VO	protocol
disease	VO	injection
disease	VO	primary vaccination
disease	VO	COVID-19 vaccine
disease	VO	dose
disease	VO	vaccine
disease	VO	vaccination
disease	MESH	amenorrhea
disease	IDO	country
disease	VO	device
drug	DRUGBANK	Levonorgestrel
disease	MESH	lifestyle
disease	IDO	history
pathway	REACTOME	SARS-CoV-2 Infection
disease	MESH	chronic illness
disease	MESH	hypertension
disease	MESH	Congestive heart failure
disease	MESH	Chronic obstructive pulmonary disease
disease	IDO	disease
disease	MESH	coronary artery disease
disease	MESH	unstable angina
disease	MESH	coronary heart disease
disease	MESH	diabetic ketoacidosis
disease	MESH	Chronic kidney disease
disease	MESH	gastroesophageal reflux disease
disease	MESH	allergy
disease	VO	influenza vaccines
drug	DRUGBANK	Polysorbate 80
disease	MESH	anaphylaxis
disease	MESH	Syndrome
disease	MESH	hypothyroidism
disease	MESH	psoriasis
drug	DRUGBANK	Prednisone
disease	IDO	blood
disease	MESH	cancer
disease	MESH	carcinoma
disease	MESH	lentigo maligna
drug	DRUGBANK	Methylergometrine
disease	MESH	carcinoma in situ
disease	MESH	alcohol abuse
disease	MESH	drug addiction
disease	MESH	Acute disease
disease	VO	time
disease	MESH	myocarditis
disease	MESH	pericarditis
disease	IDO	quality
disease	VO	organization
disease	IDO	site

(Visited 2 times, 1 visits today)